Fig. 5From: Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trialsParametric models of overall survival for studies depicted in Fig. 3. Time axis is months, vertical axis is proportion alive. All are Weibull models except where specifiedBack to article page